0.773

5.18% -0.0422

Skye Bioscience Inc (SKYE)

Overview News Price History Discussions Forecast

Skye Bioscience Inc stock is traded at $0.773, with a volume of 229.73K. It is down -5.18% in the last 24 hours and up +17.07% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Previous Close:

$0.8152

Open:

$0.8276

24h Volume:

229.73K

Relative Volume:

0.44

Market Cap:

$25.80M

Revenue:

Net Income/Loss:

$-55.92M

P/E Ratio:

-0.5482

EPS:

-1.41

Net Cash Flow:

$-43.07M

1W Performance:

+9.30%

1M Performance:

+17.07%

6M Performance:

-49.48%

1Y Performance:

-54.80%

1-Day Range:

$0.75

$0.8276

1-Week Range:

$0.6902

$0.8297

52-Week Range:

$0.5655

$5.75

Skye Bioscience Inc Stock (SKYE) Company Profile

Name

Skye Bioscience Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(858) 410-0266

Address

11250 EL CAMINO REAL, SUITE 100, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-03-10

Latest SEC Filings

SKYE's Discussions on Twitter

Compare SKYE vs MOBBW, GOODO, PSNYW, SHMD, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SKYE Skye Bioscience Inc.	3.10	12.89M	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	1.82	2.55B	0	0	0	0.00
GOODO Gladstone Commercial Corporation	19.85	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	3.70	356.14M	2.07B	-1.42B	-1.37B	-0.6765
SHMD Schmid Group N V	5.81	315.27M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	46.21	0	0	0	0	0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-06-25	Downgrade	Craig Hallum	Buy → Hold
Aug-15-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform
Sep-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-09-24	Initiated	Craig Hallum	Buy
May-23-24	Initiated	Cantor Fitzgerald	Overweight
Apr-12-24	Initiated	Oppenheimer	Outperform

View All

Skye Bioscience Inc Stock (SKYE) Latest News

Apr 13, 2026

Ideas Watch: What is the next catalyst for Skye Bioscience IncWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn

Apr 13, 2026

SKYE Technical Analysis | Trend, Signals & Chart Patterns | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill

Apr 13, 2026

Apr 09, 2026

Profit Review: Is Skye Bioscience Inc in a bullish channel2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn

Apr 09, 2026

Guidance Update: Can Skye Bioscience Inc weather a recessionTake Profit & AI Powered Market Trend Analysis - baoquankhu1.vn

Apr 09, 2026

Skye Bioscience, Inc. advances nimacimab development targeting higher-dose safety and practical dosing options - Traders Union

Apr 09, 2026

Apr 07, 2026

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit - ChartMill

Apr 07, 2026

SKYE BIOSCIENCE, INC. 8-K/A SEC Filing: Company Information, Address, and Regulatory Details (March 31, 2026) - Minichart

Apr 07, 2026

Apr 06, 2026

Skye Bioscience (NASDAQ: SKYE) reports 52‑week nimacimab results, seeks 3x share authorization - Stock Titan

Apr 06, 2026

Skye Bioscience (SKYE) seeks to triple authorized shares; nimacimab posts 22.3% weight loss signal - Stock Titan

Apr 06, 2026

Skye Bioscience (SKYE) fixes share count for repriced stock options - Stock Titan

Apr 06, 2026

Will Skye Bioscience Inc outperform the market in YEARMarket Trend Summary & Technical Buy Zone Confirmation - baoquankhu1.vn

Apr 06, 2026

Apr 05, 2026

SKYE SEC FilingsSkye Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 05, 2026

Earnings Miss: Whats the outlook for Skye Bioscience Incs sectorWeekly Investment Recap & High Accuracy Swing Trade Signals - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Skye Bioscience Signs Master Services Agreement With Lohman & Associates for Finance and Accounting Consulting - Minichart

Apr 04, 2026

Apr 03, 2026

Skye Bioscience reduces employee stock option exercise prices and appoints new CFO - Investing.com Australia

Apr 03, 2026

Skye Bioscience appoints John P. Sharp as CFO; Punit Dhillon and Tuan Diep have options repriced - TradingView — Track All Markets

Apr 03, 2026

Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO - Stock Titan

Apr 03, 2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - Bitget

Apr 03, 2026

Apr 02, 2026

Skye Bioscience doses first patient in nimacimab expansion study By Investing.com - Investing.com Australia

Apr 02, 2026

Skye Bioscience (SKYE) director receives 75,000 stock options at $0.615 strike - Stock Titan

Apr 02, 2026

Skye Bioscience (SKYE) CSO updates option awards with repricing and new grants - Stock Titan

Apr 02, 2026

Director at Skye Bioscience (NASDAQ: SKYE) receives 75,000-share stock option grant - Stock Titan

Apr 02, 2026

[Form 3/A] Skye Bioscience, Inc. Amended Initial Statement of Beneficial Ownership - Stock Titan

Apr 02, 2026

Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150 - Stock Titan

Apr 02, 2026

Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options - Stock Titan

Apr 02, 2026

Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615 - Stock Titan

Apr 02, 2026

Skye Bioscience COO reports option repricing | SKYE Insider Trading - Stock Titan

Apr 02, 2026

Skye Bioscience (SKYE) reprices CEO stock options to $0.615 strike - Stock Titan

Apr 02, 2026

Skye Bioscience, Inc. initiates expansion study of nimacimab to assess exposure and safety - Traders Union

Apr 02, 2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study - marketscreener.com

Apr 02, 2026

Skye Bioscience doses first patient in nimacimab expansion study - Investing.com

Apr 02, 2026

Mar 31, 2026

Skye Bioscience, Inc. advances nimacimab dosing to target CB1 pathway - Traders Union

Mar 31, 2026

Mar 29, 2026

SKYE PE Ratio & Valuation, Is SKYE Overvalued - Intellectia AI

Mar 29, 2026

Mar 26, 2026

Aug Wrap: How does Skye Bioscience Inc perform in inflationary periods2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn

Mar 26, 2026

Mar 20, 2026

Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail

Mar 20, 2026

Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart

Mar 20, 2026

Mar 19, 2026

Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com Australia

Mar 19, 2026

Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com

Mar 19, 2026

Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Mar 19, 2026

Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan

Mar 19, 2026

Mar 16, 2026

Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN

Mar 16, 2026

Mar 13, 2026

Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail

Mar 13, 2026

Mar 12, 2026

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail

Mar 12, 2026

Mar 11, 2026